Bio Ascend – Developing your personal brand in GI Oncology – OncoDaily
Bio Ascend – Developing your personal brand in GI Oncology / Bio Ascend, cancer, OncoDaily, Oncology
Bio Ascend – Developing your personal brand in GI Oncology / Bio Ascend, cancer, OncoDaily, Oncology
Based on the IMpower133 trial, atezolizumab plus carboplatin and etoposide (+CE) is approved as first-line treatment for ES-SCLC. The J-TAIL-2 study evaluated atezolizumab +CE in…
Mother of girl who died in 2013 reveals figures on Today programme that are welcomed by national medical director
The idea that hearts carry feelings and memories is nothing new.
Recent research points to three types of behaviour that can help managers bridge physical distances with staff.
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma Hematology Disease Topics &…
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma Hematology Disease Topics &…
Cancer Research UK concerned over dwindling participation in breast and cervical cancer screening
Ethics of posthumous scholarly authorship in the sciences
GloRilla donated $25,000 for a new media center for her alma mater Melrose High.
The pathway that activates AKT3 to drive epithelial-to-mesenchymal transition in pancreatic cancer is revealed.